Synthesis and biological evaluation of modified peptide derivatives targeting the SARS-CoV-2 nsp3 macrodomain (Mac1) replication domain

dc.contributor.authorÖzmen, Özge
dc.contributor.authorOruçoğlu, Betül
dc.contributor.authorDingiş Birgül, Serap İpek
dc.contributor.authorÖztürk Civelek, Dilek
dc.contributor.authorGül, Şeref
dc.contributor.authorAkdemir, Atilla
dc.contributor.authorSönmez, Fatih
dc.contributor.authorZengin Kurt, Belma
dc.date.accessioned2026-05-04T08:31:54Z
dc.date.issued2026
dc.departmentİstanbul Kent Üniversitesi, Fakülteler, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü
dc.description.abstractModified peptide derivatives (D1−D15) containing hydrophobic (phenylalanine and tryptophan) and positively charged (histidine) amino acid residues, were designed and synthesized. The cytotoxicity of the compounds was evaluated in healthy (CCD1079Sk) cell lines, revealing no significant cytotoxic effects and indicating favorable safety profiles. Molecular modeling studies were performed for all compounds and indicated that compounds D13, D14, and D15 form favorable binding interactions with the Nsp3 macrodomain 1 (Mac1) active site. The affinity of these compounds is expected to be moderate to high, although lower than that of ADP ribose. Subsequent bioactivity assays, performed using a cell-based SARS-CoV-2 replicon system, revealed that compound D15 displays the most potent inhibition of viral replication (IC50 = 22.2 μM (95% CI: 15.4−35.7 μM)), while compound D14 shows the second most potent inhibitory activity (IC50 = 61.2 μM (95% CI: 39.2− 143.9 μM)). Considering these results, it has been shown that compounds with a histidine side chain exhibit higher biological activity, suggesting a structure−activity relationship driven by positively charged residues.
dc.identifier.citationÖzmen Ö., Oruçoğlu B., Dingiş Birgül Sİ., Öztürk Civelek D., Gül Ş., Akdemir A., Sönmez F., Zengin Kurt B. (2026). Synthesis and biological evaluation of modified peptide derivatives targeting the SARS-CoV-2 nsp3 macrodomain (Mac1) replication domain. ACS Omega.
dc.identifier.doi10.1021/acsomega.6c02033
dc.identifier.orcid0009-0003-3258-8603
dc.identifier.orcid0009-0008-2526-608X
dc.identifier.orcid0000-0003-2242-4296
dc.identifier.orcid0000-0003-2485-891X
dc.identifier.orcid0000-0002-5613-1339
dc.identifier.orcid0000-0001-8416-0471
dc.identifier.orcid0000-0001-7486-6374
dc.identifier.orcid0000-0002-4663-5402
dc.identifier.urihttps://pubs.acs.org/doi/10.1021/acsomega.6c02033?src=getftr&utm_source=clarivate&getft_integrator=clarivate
dc.identifier.urihttps://hdl.handle.net/20.500.12780/1477
dc.identifier.wosWOS:001748965900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherACS Publications
dc.relation.ispartofACS Omega
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectLigands
dc.subjectMonomers
dc.subjectNoncovalent interactions
dc.subjectPeptides and proteins
dc.subjectSARS-CoV-2
dc.titleSynthesis and biological evaluation of modified peptide derivatives targeting the SARS-CoV-2 nsp3 macrodomain (Mac1) replication domain
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
akdemir,atilla.pdf
Boyut:
5.52 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text

Lisans paketi

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: